Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Tenax Therapeutics, Inc.NASDAQ: TENX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 9.9% from a year ago
Total current assets stood at $123.18M at the end of Q1 FY2026, up 9.9% from a year earlier and up 18.2% from the prior quarter. Over 3 fiscal years it compounded at +219.1% a year.
Context
- Total current assets amounted to 100.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +9.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 104.23M USD
- Year-over-year change
- +7.8%
- 4-year CAGR
- +106.9%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.23M | +7.8% |
| FY2024 | 2024-12-31 | 96.69M | +727.5% |
| FY2023 | 2023-12-31 | 11.68M | +264.1% |
| FY2022 | 2022-12-31 | 3.21M | -43.6% |
| FY2021 | 2021-12-31 | 5.69M | — |
Total Current Assets vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 total current assets of $123.18M is the 2nd highest of the 7 companies compared; the peer median is $91.05M.
- Its year-over-year change of +9.9% is the 4th highest of 7, against a peer median of +4.6%.
- Total current assets amounts to 100.0% of total assets for TENX, versus a peer median of 84.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $79.73B | +512730.9% | +27.4% | 83.9% | |
| Mar 2026 | $123.18M | +9.9% | +219.1% | 100.0% | |
| Jun 2026 | $107.94M | +1059.6% | +66.0% | 45.3% | |
| Mar 2026 | $94.62M | -32.6% | +17.2% | 67.1% | |
| Mar 2026 | $87.49M | +25.8% | -15.3% | 100.0% | |
| Mar 2026 | $57.2M | -16.7% | +5.5% | 89.8% | |
| Mar 2026 | $32.76M | -17.0% | +2.8% | 84.5% | |
| Peer median (excluding TENX) | $91.05M | +4.6% | +11.4% | 84.2% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.